Scleral Contact Lens Impact on Tear Film Cytokines
Investigator Initiated
- Principal Investigator: Curtis Brandt, PhD
- Clinical Collaborator: Michele Martin, OD
- Study Coordinator: Chris Smith
Study Objective
To use scleral contact lenses for increased comfort and vision in dry eye and/or keratoconus patients by decreasing the production of pro-inflammatory cytokines.
Study Design
The study will include three clinic visits over a 3-month period. Visits will consist of an Ocular Surface Disease Index (OSDI) questionnaire, tear film collection, and slit lamp photography in addition to regular clinical activities.
Inclusion Criteria:
- Male or female patients ≥ 18 years of age with confirmed diagnosis of dry eye and/or keratoconus
- Ability to discontinue topical anti-inflammatory medications for 10 days prior to Visit 1
- Systemically stable with GVHD under control as determined by referring physician or transplant medicine team, if applicable
- Scleral contact lenses prescribed by treating eye doctor as standard-of-care for dry eye and/or keratoconus
Exclusion Criteria:
- Any active ocular disease other than dry eye and/or keratoconus
- Contact lens wear
- Any ocular surgery in the last 6 months
- Any topical medicine other than lubricants or tears
- Systemic anti-inflammatory therapies for at least 3 months before initial sample collection
- Relapse of malignancy
- Active infection in any part of the body
Contact Chris Smith with questions at (608) 263-7169
For more information about this study, please visit clinicaltrials.gov